Portal de Periódicos da CAPES

Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease

2006; Wiley; Volume: 40; Issue: 1 Linguagem: Inglês

10.1111/j.1600-0757.2005.00138.x

1600-0757

Janet H. Southerland, George W. Taylor, Kevin Moss, James D. Beck, Steven Offenbacher,

Inflammatory mediators and NSAID effects

Periodontology 2000Volume 40, Issue 1 p. 130-143 Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease Janet H. Southerland, Janet H. SoutherlandSearch for more papers by this authorGeorge W. Taylor, George W. TaylorSearch for more papers by this authorKevin Moss, Kevin MossSearch for more papers by this authorJames D. Beck, James D. BeckSearch for more papers by this authorSteven Offenbacher, Steven OffenbacherSearch for more papers by this author Janet H. Southerland, Janet H. SoutherlandSearch for more papers by this authorGeorge W. Taylor, George W. TaylorSearch for more papers by this authorKevin Moss, Kevin MossSearch for more papers by this authorJames D. Beck, James D. BeckSearch for more papers by this authorSteven Offenbacher, Steven OffenbacherSearch for more papers by this author First published: 04 January 2006 https://doi.org/10.1111/j.1600-0757.2005.00138.xCitations: 128Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y, Kumar A. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 2004: 42: 341–353. 2 Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000: 86: 897–902. 3 Alexiewicz JM, Kumar D, Smogorzewski M, Klin M, Massry SG. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med, 1995: 123: 919–924. 4 American Diabetes Association. Direct and indirect costs of diabetes in the United States [WWW document]. http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. 5 Andresen JL, Rasmussen LM, Ledet T. Diabetic macroangiopathy and atherosclerosis. Diabetes 1996: 45 (Suppl. 3): S91–S94. 6 Araya AV, Pavez V, Perez C, Gonzalez F, Columbo A, Aguirre A, Schiattino I, Aguillon JC. Ex vivo lipopolysaccharide (LPS)-induced TNF-alpha, IL-1beta, IL-6 and PGE2 secretion in whole blood from Type 1 diabetes mellitus patients with or without aggressive periodontitis. Eur Cytokine Netw 2003: 14: 128–133. 7 Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004: 113: 451–463. 8 Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004: 63: 582–592. 9 Baumann H, Jahreis GP, Morella KK. Interaction of cytokine- and glucocorticoid-response elements of acute-phase plasma protein genes. Importance of glucocorticoid receptor level and cell type for regulation of the elements from rat alpha 1-acid glycoprotein and beta-fibrinogen genes. J Biol Chem 1990: 265: 22275–22281. 10 Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev 1996: 7: 175–190. 11 Beck JD, Slade G, Offenbacher S. Oral disease, cardiovascular disease and systemic inflammation. Periodontol 2000 2000: 23: 110–120. 12 Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004: 382: 393–409. 13 Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997: 17: 3–9. 14 Bowie A, O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000: 59: 13–23. 15 Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993: 143: 1699–1712. 16 Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW, Dantzer R, Kelley KW. IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts. J Immunol 2004: 172: 7713–7720. 17 Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994: 43: 836–841. 18 Brownlee M. The pathological implications of protein glycation. Clin Invest Med 1995: 18: 275–281. 19 Cairo F, Gaeta C, Dorigo W, Oggioni MR, Pratesi C, Pini Prato GP, Pozzi G. Periodontal pathogens in atheromatous plaques. A controlled clinical and laboratory trial. J Periodontal Res 2004: 39: 442–446. 20 Cerami A, Vlassara H, Brownlee M. Role of advanced glycosylation products in complications of diabetes. Diabetes Care 1988: 11 (Suppl. 1): 73–79. 21 Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990: 39: 807–814. 22 Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004: 6: 1219–1225. 23 Chisolm GM, Irwin KC, Penn MS. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 1992: 41 (Suppl. 2): 61–66. 24 Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002: 71: 433–444. 25 Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997: 49: 15–19. 26 De Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004: 279: 17070–17078. 27 DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol 2004: 4: 301–305. 28 Dinarello CA, Mier JW. Interleukins. Annu Rev Med 1986: 37: 173–178. 29 Di Paola R, Marzocco S, Mazzon E, Dattola F, Rotondo F, Britti D, De Majo M, Genovese T, Cuzzocrea S. Effect of aminoguanidine in ligature-induced periodontitis in rats. J Dent Res 2004: 83: 343–348. 30 Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 1992: 89: 2873–2877. 31 Donald R, Ballard DW, Hawiger J. Proteolytic processing of NF-kappa B/I kappa B in human monocytes. ATP-dependent induction by pro-inflammatory mediators. J Biol Chem 1995: 270: 9–12. 32 Drash AL. What do epidemiologic observations tell us about the etiology of insulin dependent diabetes mellitus? Schweiz Med Wochenschr 1990: 120: 39–45. 33 Ellis RW. Infection and coronary heart disease. J Med Microbiol 1997: 46: 535–539. 34 Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004: 14: 228–232. 35 Fahey TJ 3rd, Sadaty A, Jones WG 2nd, Barber A, Smoller B, Shires GT. Diabetes impairs the late inflammatory response to wound healing. J Surg Res 1991: 50: 308–313. 36 Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992: 41 (Suppl. 2): 97–101. 37 Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992: 12: 1496–1502. 38 Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989: 125: 267–274. 39 Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, Dinarello CA, Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992: 33: 1765–1776. 40 Ferreri NR, Howland WC, Spiegelberg HL. Release of leukotrienes C4 and B4 and prostaglandin E2 from human monocytes stimulated with aggregated IgG, IgA, and IgE. J Immunol 1986: 136: 4188–4193. 41 Fibbe WE, Falkenburg JH, Schaafsma MR, Willemze R. The hematopoietic activities of interleukin-1. Biotherapy 1989: 1: 263–271. 42 Fiske J. Diabetes mellitus and oral care. Dent Update 2004: 31 (190–196): 198. 43 Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, Wilson PW, Savage PJ. Trends in cardiovascular complications of diabetes. JAMA 2004: 292: 2495–2499. 44 Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1 beta-8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000: 71: 1535–1545. 45 Garcia-Welsh A, Schneiderman JS, Baly DL. Interleukin-1 stimulates glucose transport in rat adipose cells. Evidence for receptor discrimination between IL-1 beta and IL-1 alpha. FEBS Lett 1990: 269: 421–424. 46 Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003: 52: 453–462. 47 Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998: 16: 225–260. 48 Ginsberg HN, Tuck C. Diabetes and dyslipidemia. Curr Diab Rep 2001: 1: 93–95. 49 Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988: 168: 1041–1059. 50 Grunfeld C, Soued M, Adi S, Moser AH, Dinarello CA, Feingold KR. Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. Endocrinology 1990: 127: 46–54. 51 Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care 1998: 21 (Suppl. 3): C3–C6. 52 Hallmon WW, Mealey BL. Implications of diabetes mellitus and periodontal disease. Diabetes Educ 1992: 18: 310–315. 53 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996: 39: 1577–1583. 54 Hardardottir I, Doerrler W, Feingold KR, Grunfeld C. Cytokines stimulate lipolysis and decrease lipoprotein lipase activity in cultured fat cells by a prostaglandin independent mechanism. Biochem Biophys Res Commun 1992: 186: 237–243. 55 Hasegawa T, Kosaki A, Kimura T, Matsubara H, Mori Y, Okigaki M, Masaki H, Toyoda N, Inoue-Shibata M, Kimura Y, Nishikawa M, Iwasaka T. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 2003: 171: 211–218. 56 Haskill S, Beg AA, Tompkins SM, Morris JS, Yurochko AD, Sampson-Johannes A, Mondal K, Ralph P, Baldwin AS Jr. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 1991: 65: 1281–1289. 57 Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003: 91: 12A–16A. 58 Hobbs CG, Kodikara M, Gray R, Bordin P, Robinson A, Pacy PJ, Venkatesan S, Halliday D. Lipoproteins in non-insulin dependent diabetes mellitus (NIDDM). Biochem Soc Trans 1996: 24: 153S. 59 Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2003. Diabetes Care 2002: 26: 917–932. 60 Hove KA, Stallard RE. Diabetes and the periodontal patient. J Periodontol 1970: 41: 713–718. 61 Hugoson A, Thorstensson H, Falk H, Kuylenstierna J. Periodontal conditions in insulin-dependent diabetics. J Clin Periodontol 1989: 16: 215–223. 62 Iehara N, Takeoka H, Tsuji H, Yamada Y, Kita T, Doi T. Advanced glycosylation end products modulate transcriptional regulations on mesangial cells. Contrib Nephrol 1996: 118: 141–146. 63 Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a d-domain-like docking site. FEBS Lett 2003: 550: 107–113. 64 Jang MK, Kim JY, Jeoung NH, Kang MA, Choi MS, Oh GT, Nam KT, Lee WH, Park YB. Oxidized low-density lipoproteins may induce expression of monocyte chemotactic protein-3 in atherosclerotic plaques. Biochem Biophys Res Commun 2004: 323: 898–905. 65 Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care 2003: 26: 810–818. 66 John WG, Lamb EJ. The Maillard or browning reaction in diabetes. Eye 1993: 7 (Pt 2): 230–237. 67 Kapp C. World Health Report charts way forward on CV disease prevention. Lancet Neurol 2002: 1: 461. 68 Katz PP, Wirthlin MR Jr, Szpunar SM, Selby JV, Sepe SJ, Showstack JA. Epidemiology and prevention of periodontal disease in individuals with diabetes. Diabetes Care 1991: 14: 375–385. 69 Kinane DF. Aetiology and pathogenesis of periodontal disease. Ann R Australas Coll Dent Surg 2000: 15: 42–50. 70 Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992: 258: 593–597. 71 Klein RL, Wohltmann HJ, Lopes-Virella MF. Influence of glycemic control on interaction of very-low- and low-density lipoproteins isolated from type I diabetic patients with human monocyte-derived macrophages. Diabetes 1992: 41: 1301–1307. 72 Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H, Mori Y, Okigaki M, Toyoda N, Masaki H, Inoue-Shibata M, Nishikawa M, Iwasaka T. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004: 89: 5423–5428. 73 Kottra CJ. Infection in the compromised host – an overview. Heart Lung 1983: 12: 10–14. 74 Krakauer T. Molecular therapeutic targets in inflammation. cyclooxygenase and NF-kappaB. Curr Drug Targets Inflamm Allergy 2004: 3: 317–324. 75 Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003: 5 (Suppl. 1): S19–S27. 76 Laakso M. Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim Care 1999: 26: 829–839. 77 Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. Periodontol 2000 2000: 23: 50–62. 78 Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, Chait A, Bornfeldt KE. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 2004: 53: 3217–3225. 79 Larkin JG, Frier BM, Ireland JT. Diabetes mellitus and infection. Postgrad Med J 1985: 61: 233–237. 80 Liu Y, Gutterman DD. The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol 2002: 38: 43–49. 81 Loe H. Periodontal disease as we approach the year 2000. J Periodontol 1994: 65: 464–467. 82 Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 1992: 41 (Suppl. 2): 86–91. 83 Lovegrove JM. Dental plaque revisited: bacteria associated with periodontal disease. J N Z Soc Periodontol 2004: 87: 7–21. 84 Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997: 241: 485–492. 85 Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes 1992: 41 (Suppl. 2): 67–73. 86 Malavige GN. Does leptin resistance contribute to infections in patients with diabetes? Mol Pathol 2003: 56: 248. 87 Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression. inhibitory effect of antioxidants. J Leukoc Biol 2004: 75: 1062–1069. 88 Mandell RL, Dirienzo J, Kent R, Joshipura K, Haber J. Microbiology of healthy and diseased periodontal sites in poorly controlled insulin dependent diabetics. J Periodontol 1992: 63: 274–279. 89 Marinkovic S, Jahreis GP, Wong GG, Baumann H. IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 1989: 142: 808–812. 90 Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, De Caterina R, Basta G, Wautier MP, Wautiers JL. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004: 53: 2662–2668. 91 Mattila KJ. Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med 1989: 225: 293–296. 92 May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 1997: 8: 63–73. 93 Michalek SM, Katz J, Childers NK, Martin M, Ballovetz DF. Microbial/host interactions: mechanisms involved in host responses to microbial antigens. Immunol Res 2002: 26: 223–234. 94 Miller LS, Manwell MA, Newbold D, Reding ME, Rasheed A, Blodgett J, Kornman KS. The relationship between reduction in periodontal inflammation and diabetes control: a report of 9 cases. J Periodontol 1992: 63: 843–848. 95 Miranda LP, Tao T, Jones A, Chernushevich I, Standing KG, Geczy CL, Alewood PF. Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett 2001: 488: 85–90. 96 Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2003: 27: 88–94. 97 Molvig J, Baek L, Christensen P, Manogue KR, Vlassara H, Platz P, Nielsen LS, Svejgaard A, Nerup J. Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences. Scand J Immunol 1988: 27: 705–716. 98 Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996: 45 (Suppl. 3): S67–S72. 99 Moore PA, Weyant RJ, Mongelluzzo MB, Myers DE, Rossie K, Guggenheimer J, Block HM, Huber H, Orchard T. Type 1 diabetes mellitus and oral health: assessment of periodontal disease. J Periodontol 1999: 70: 409–417. 100 Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983: 24: 1070–1076. 101 Muhammad S. Epidemiology of diabetes and obesity in the United States. Compend Contin Educ Dent 2004: 25: 195–198, 200, 202, quiz 204. 102 Musson RA, Shafran H, Henson PM. Intracellular levels and stimulated release of lysosomal enzymes from human peripheral blood monocytes and monocyte-derived macrophages. J Reticuloendothel Soc 1980: 28: 249–264. 103 Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway. divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998: 187: 2097–2101. 104 Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993: 143: 1649–1656. 105 Nathan CF, Murray HW, Cohn ZA. The macrophage as an effector cell. N Engl J Med 1980: 303: 622–626. 106 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetes across the United States. In: National Diabetes Information Clearinghouse (NDIC).[WWW document]. http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. 107 Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992: 267: 14998–15004. 108 Neil A. Diabetes and cardiovascular disease. Diabetes Obes Metab 2003: 5 (Suppl. 1): S11–S18. 109 Nerup J, Mandrup-Poulsen T, Molvig J. The HLA–IDDM association: implications for etiology and pathogenesis of IDDM. Diabetes Metab Rev 1987: 3: 779–802. 110 Nesto R. CHD. a major burden in type 2 diabetes. Acta Diabetol 2001: 38 (Suppl. 1): S3–S8. 111 Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol 2003: 42: 201–206. 112 O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 1996: 94: 1216–1225. 113 O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Biochem Soc Trans 2000: 28: 557–563. 114 Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 1997: 14: 216–248. 115 Papapanou PN. Epidemiology of periodontal diseases: an update. J Int Acad Periodontol 1999: 1: 110–116. 116 Peppa M, Uribarri J, Vlassara H. Advanced glycoxidation. A new risk factor for cardiovascular disease? Cardiovasc Toxicol 2002: 2: 275–287. 117 Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. Diabetologia 2004: 47: 170–184. 118 Preshaw PM, Seymour RA, Heasman PA. Current concepts in periodontal pathogenesis. Dent Update 2004: 31: 574–578. 119 Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity 1994: 1: 509–516. 120 Pussinen PJ, Mattila K. Periodontal infections and atherosclerosis: mere associations? Curr Opin Lipidol 2004: 15: 583–588. 121 Qi M, Miyakawa H, Kuramitsu HK. Porphyromonas gingivalis induces murine macrophage foam cell formation. Microb Pathog 2003: 35: 259–267. 122 Quinn L. Educating patients with diabetes about cardiovascular disease risk. Prog Cardiovasc Nurs 2004: 19: 107–113. 123 Radulescu L, Stancu C, Antohe F. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins. Med Sci Monit 2004: 10: BR207–214. 124 Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 2004: 66: 1099–1106. 125 Raynes JG. The acute phase response. Biochem Soc Trans 1994: 22: 69–74. 126 Reaven P. Metabolic syndrome. J Insur Med 2004: 36: 132–142. 127 Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, Von Herrath MG, Chait A, Bornfeldt KE. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004: 114: 659–668. 128 Rizvi AA. Type 2 diabetes: epidemiologic trends, evolving pathogenic concepts, and recent changes in therapeutic approach. South Med J 2004: 97: 1079–1087. 129 Rodel J, Prochnau D, Prager K, Pentcheva E, Hartmann M, Straube E. Increased production of matrix metalloproteinases 1 and 3 by smooth muscle cells upon infection with Chlamydia pneumoniae. FEMS Immunol Med Microbiol 2003: 38: 159–164. 130 Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002: 51: 1319–1336. 131 Ryseck RP, Weih F, Carrasco D, Bravo R. RelB, a member of the Rel/NF-kappa B family of transcription factors. Braz J Med Biol Res 1996: 29: 895–903. 132 Salvi GE, Beck JD, Offenbacher S. PGE2, IL-1 beta, and TNF-alpha responses in diabetics as modifiers of periodontal disease expression. Ann Periodontol 1998: 3: 40–50. 133 Salvi GE, Lawrence HP, Offenbacher S, Beck JD. Influence of risk factors on the pathogenesis of periodontitis. Periodontol 2000 1997: 14: 173–201. 134 Salvi GE, Yalda B, Collins JG, Jones BH, Smith FW, Arnold RR, Offenbacher S. Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. J Periodontol 1997: 68: 127–135. 135 Santamaria P, Gehrz RC, Bryan MK, Barbosa JJ. Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes. Quantitative differences at the polymorphic level. J Immunol 1989: 143: 913–922. 136 Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 1994: 91: 8807–8811. 137 Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996: 45 (Suppl. 3): S77–S80. 138 Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993: 91: 2155–2168. 139 Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999: 84: 489–497. 140 Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Klein W. LDL oxidation and coronary atherosclerosis. Lancet 1992: 340: 123. 141 Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987: 262: 8390–8394. 142 Semenkovich CF, Heinecke JW. The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 1997: 46: 327–334. 143 Shapira L, Warbington M, Van Dyke TE. TNF alpha and IL-1 beta in serum of LJP patients with normal and defective neutrophil chemotaxis. J Periodontal Res, 1994: 29: 371–373. 144 Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002: 252: 440–447. 145 Slade GD, Offenbacher S, Beck JD, Heiss G, Pankow JS. Acute-phase inflammatory response to periodontal disease in the US population. J Dent Res 2000: 79: 49–57. 146 Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J Clin Periodontol 1998: 25: 34–144. 147 Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 2004: 11: 521–528. 148 Storz P, Doppler H, Wernig A, Pfizenmaier K, Muller G. Cross-talk mechanisms in the development of insulin resistance of skeletal muscle cells palmitate rather than tumour necrosis factor inhibits insulin-dependent protein kinase B (PKB)/Akt stimulation and glucose uptake. Eur J Biochem 1999: 266: 17–25. 149 Streja D. Metabolic syndrome and other factors associated with increased risk of diabetes. Clin Cornerstone 2004: 6 (Suppl. 3): S14–S29. 150 Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000: 405: 354–360. 151 Tanimoto K, Ohno S, Fujimoto K, Honda K, Ijuin C, Tanaka N, Doi T, Nakahara M, Tanne K. Proinflammatory cytokines regulate the gene expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. Connect Tissue Res 2001: 42: 187–195. 152 Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. Ann Periodontol 2001: 6: 99–112. 153 Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M. Glycemic control and alveolar bone loss progression in type 2 diabetes. Ann Periodontol 1998: 3: 30–39. 154 Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995: 80: 529–532. 155 Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997: 18: 428–432. 156 Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002: 30: 182–192. 157 Tsilibary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht LT. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem 1988: 263: 4302–4308. 158 Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004: 24: 469–473. 159 Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002: 105: 81–92. 160 Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994: 124: 19–30. 161 Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004: 95: 233–238. 162 Weitzman S, Wang C, Rosamond WD, Chambless LE, Cooper LS, Shahar E, Goff DC. Is diabetes an independent risk factor for mortality after myocardial infarction? The ARIC (Atherosclerosis Risk in Communities) Surveillance Study. Acta Diabetol 2004: 41: 77–83. 163 Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997: 7: 837–847. 164 Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004: 44: 397–405. 165 Wogensen LD, Mandrup-Poulsen T, Markholst H, Molvig J, Lernmark A, Holst JJ, Dinarello CA, Nerup J. Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. Acta Endocrinol (Copenh) 1988: 117: 302–306. 166 Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998: 95: 4630–4634. 167 Wulczyn FG, Krappmann D, Scheidereit C. The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J Mol Med 1996: 74: 749–769. 168 Yalda B, Offenbacher S, Collins JG. Diabetes as a modifier of periodontal disease expression. Periodontol 2000 1994: 6: 37–49. 169 Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001: 50: 1495–1504. 170 Yet SF, Melo LG, Layne MD, Perrella MA. Heme oxygenase 1 in regulation of inflammation and oxidative damage. Methods Enzymol 2002: 353: 163–176. 171 Yosefy C. Hyperglycaemia and its relation to cardiovascular morbidity and mortality: has it been resolved? Acta Diabetol 2003: 40 (Suppl. 2): S380–S388. 172 Yuan K, Chang CJ, Hsu PC, Sun HS, Tseng CC, Wang JR. Detection of putative periodontal pathogens in non-insulin-dependent diabetes mellitus and non-diabetes mellitus by polymerase chain reaction. J Periodontal Res 2001: 36: 18–24. 173 Zimmet PZ, McCarty DJ, De Courten MP. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997: 11: 60–68. Citing Literature Volume40, Issue1February 2006Pages 130-143 ReferencesRelatedInformation